The UVA Cancer Center seeks adult males ages 18 and over with metastatic castration resistant prostate cancer (mCRPC) for a clinical trial.
The purpose of this study is to evaluate an experimental drug, which is a protein degrader (ARV-110), in patients with mCRPC. Disease response and good and bad effects of the drug will be studied as part of this trial.
Study specific tests will be provided at no cost to you.
No Compensation; Reimbursement: Up to $175 per night for hotel stay.